Phosphodiesterase-IN-2

• UNSPSC Description:

  Phosphodiesterase-IN-2 (Compound C7) is a selective, orally active inhibitor for phosphodiesterase 10A (PDE10A), with an IC50 of 11.9 nM. Phosphodiesterase-IN-2 improves the stability of liver microsomes, and lowers BBB permeability. Phosphodiesterase-IN-2 exhibits good pharmacokinetic characters, and attenuates isoprenaline (HY-108353)-induced cardiac hypertrophic in mouse models[1].

• Target Antigen:

  Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/phosphodiesterase-in-2.html

• Solubility:

  10 mM in DMSO

• Smiles:

  FC(F)(F)C(C=C1C2=CC(C)=NC=C2)=NN1C3=CC=C(OCC4=NC5=C(C=CC=C5)C(C(N6CC7(CNC7)C6)=O)=C4)C=C3

• Molecular Weight:

  584.59

• References & Citations:

  [1]Yuan H, et al., Discovery of 3-trifluoromethyl-substituted pyrazoles as selective phosphodiesterase 10A inhibitors for orally attenuating isoprenaline-induced cardiac hypertrophy[J]. Chinese Chemical Letters, 2024: 109965.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  3047610-96-5